JP2023540025A5 - - Google Patents

Info

Publication number
JP2023540025A5
JP2023540025A5 JP2023513278A JP2023513278A JP2023540025A5 JP 2023540025 A5 JP2023540025 A5 JP 2023540025A5 JP 2023513278 A JP2023513278 A JP 2023513278A JP 2023513278 A JP2023513278 A JP 2023513278A JP 2023540025 A5 JP2023540025 A5 JP 2023540025A5
Authority
JP
Japan
Prior art keywords
approximately
pharmaceutical composition
seq
amino acid
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023513278A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023540025A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2021/057802 external-priority patent/WO2022043900A1/en
Publication of JP2023540025A publication Critical patent/JP2023540025A/ja
Publication of JP2023540025A5 publication Critical patent/JP2023540025A5/ja
Pending legal-status Critical Current

Links

JP2023513278A 2020-08-26 2021-08-26 二重特異性egfr/c-met抗体を含む安定な製剤 Pending JP2023540025A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063070440P 2020-08-26 2020-08-26
US63/070,440 2020-08-26
PCT/IB2021/057802 WO2022043900A1 (en) 2020-08-26 2021-08-26 Stable formulations comprising a bispecific egfr/c-met antibody

Publications (2)

Publication Number Publication Date
JP2023540025A JP2023540025A (ja) 2023-09-21
JP2023540025A5 true JP2023540025A5 (cg-RX-API-DMAC7.html) 2024-09-02

Family

ID=80352835

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023513278A Pending JP2023540025A (ja) 2020-08-26 2021-08-26 二重特異性egfr/c-met抗体を含む安定な製剤

Country Status (17)

Country Link
US (1) US20220064307A1 (cg-RX-API-DMAC7.html)
EP (1) EP4204456A4 (cg-RX-API-DMAC7.html)
JP (1) JP2023540025A (cg-RX-API-DMAC7.html)
KR (1) KR20230057400A (cg-RX-API-DMAC7.html)
CN (1) CN116194485A (cg-RX-API-DMAC7.html)
AR (2) AR123340A1 (cg-RX-API-DMAC7.html)
AU (1) AU2021333882A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023003373A2 (cg-RX-API-DMAC7.html)
CA (1) CA3192630A1 (cg-RX-API-DMAC7.html)
CR (1) CR20230102A (cg-RX-API-DMAC7.html)
EC (1) ECSP23013655A (cg-RX-API-DMAC7.html)
IL (1) IL300895A (cg-RX-API-DMAC7.html)
JO (1) JOP20230040A1 (cg-RX-API-DMAC7.html)
MX (1) MX2023002367A (cg-RX-API-DMAC7.html)
PE (1) PE20231370A1 (cg-RX-API-DMAC7.html)
TW (1) TWI907491B (cg-RX-API-DMAC7.html)
WO (1) WO2022043900A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202308689A (zh) * 2021-04-21 2023-03-01 美商健生生物科技公司 高濃度的雙特異性抗體調配物
CN119790073A (zh) 2022-06-30 2025-04-08 詹森生物科技公司 使用抗EGFR/抗Met抗体治疗胃癌或食道癌
WO2024109914A1 (zh) * 2022-11-24 2024-05-30 江苏恒瑞医药股份有限公司 一种包含特异性结合hgfr和egfr的双特异性抗体的药物组合物
KR20260051102A (ko) * 2023-07-07 2026-04-15 쓰촨 케룬-바이오테크 바이오파마수티컬 컴퍼니 리미티드 Egfr/c-met 이중특이적 결합 단백질 및 이의 용도
WO2025079020A1 (en) 2023-10-12 2025-04-17 Janssen Biotech, Inc. First line treatment in egfr exon 20 insertion-mutated advanced non-small cell lung cancer
CN121045388A (zh) * 2024-05-30 2025-12-02 英百瑞(杭州)生物医药有限公司 针对人c-Met和人EGFR的双特异性抗体及其用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1865986B1 (en) * 2005-03-08 2016-02-17 Pfizer Products Inc. Anti-ctla-4 antibody compositions
RU2013155695A (ru) * 2011-06-30 2015-08-10 Дженентек, Инк. Препараты антител против с-мет
KR102373193B1 (ko) * 2012-11-21 2022-03-10 얀센 바이오테크 인코포레이티드 이중특이성 EGFR/c-Met 항체
RS61659B1 (sr) * 2016-05-17 2021-04-29 Abbvie Biotherapeutics Inc Konjugati antitelo lek anti-cmet i metode za njihovu upotrebu
TW201922780A (zh) * 2017-09-25 2019-06-16 美商健生生物科技公司 以抗il12/il23抗體治療狼瘡之安全且有效之方法
EP3688033A4 (en) * 2017-09-29 2021-06-23 Janssen Biotech, Inc. NEW FORMULATIONS THAT STABILIZE LOW DOSE ANTIBODY COMPOSITIONS
TW202308689A (zh) * 2021-04-21 2023-03-01 美商健生生物科技公司 高濃度的雙特異性抗體調配物

Similar Documents

Publication Publication Date Title
KR102397713B1 (ko) 안정한 액체 약제학적 제제
JP2024544523A5 (cg-RX-API-DMAC7.html)
FI4249512T3 (fi) Stabiili vasta-aineformulaatio
JP2024514344A5 (cg-RX-API-DMAC7.html)
JP2022532927A5 (cg-RX-API-DMAC7.html)
CN115666649B (zh) 一种新型冠状病毒抗体的药物组合物及其用途
AR124067A2 (es) Formulaciones estables que comprenden un anticuerpo biespecífico para egfr / c-met
CN106999581A (zh) 含有高浓度抗vegf抗体的稳定蛋白质溶液剂型
MX2015002411A (es) Formulaciones de anticuerpos y proteinas.
MX2008012295A (es) Formulacion de un anticuerpo monoclonal humano anti-igf-1r.
JP2022036932A5 (cg-RX-API-DMAC7.html)
JP2024515968A5 (cg-RX-API-DMAC7.html)
JP2024506940A5 (cg-RX-API-DMAC7.html)
CN114762678B (zh) 抗tigit抗体药物组合物及其用途
CL2024000232A1 (es) Composición farmacéutica de anticuerpo anti-pd-1 y uso de la misma
JP2024538140A5 (cg-RX-API-DMAC7.html)
JP2025500784A5 (cg-RX-API-DMAC7.html)
EP3958840A1 (en) The use of low molecular weight polyvinylpyrrolidone (pvp) to reduce viscosity of high concentration protein formulations
JP2022519796A5 (cg-RX-API-DMAC7.html)
JP2022519796A (ja) 抗pcsk9抗体を含む安定製剤
CA3182940A1 (en) An improved process of storing and preparing the protein formulation
RU2025126086A (ru) Композиции, содержащие биспецифическое антитело к gprc5d/cd3
CA3115708C (en) Formulations of anti-rsv antibodies and methods of use thereof
CN119258013A (zh) 包含抗α4β7抗体的药物制剂
CN119367531A (zh) 抗cd3×cd20双特异性抗体的药物组合物